Utah’s business landscape is rich with professionals who have le...Read More
Social Media and Employers: Friends or Enemies?
The Case for HSAs
Time to Show Up
Make a Move
In the Lab
Rent to Own
Back from the Dead
A Breath of Fresh Air
Travel & Tourism
Salt Lake City – EastGate Acquisitions Corporation, a pharmaceutical company, announced it has received a research grant from the Ontario Brain Institute for its Lorazepam Spray development.
The grant was issued for the purpose to study the administration of a transmucosal Lorazepam Spray for the treatment of epileptic seizures in outpatient settings. The company has entered into a collaboration with a leading neurologist, Dr. Peter Carlen, at the Toronto Western Hospital who will serve as a principal investigator on this trial.
The intraoral Lorazepam Spray is a new transmucosal non-invasive solution for the treatment of acute and repetitive seizures. The primary goal of this project is to provide a safe and effective anti-seizure medication to a patient to stop seizures in the shortest period of time. In addition to being self-administered, an oral administration provides the flexibility to any available person on the scene, be it family members, caregivers or paramedics. Another key benefit of the Lorazepam Spray is that it can be used at any point during a seizure, even if the patient's mouth is clenched shut as it can be applied directly to the gum or lip mucosa.
"We are excited about this development as the Ontario Brain Institute grant serves as a significant jump-start for the company's overall financing plans for the technology's platform," said Anna Gluskin, CEO of EastGate Acquisitions Corporation. "Our innovative technology platform based on a self-nanoemulsion formulation will directly address patient needs for fast onset of treatment and encourage self-administration with the goal of minimizing hospital care and have a positive impact on massive health care costs facing today's healthcare system.”